Member Info for 86KB

24p would be only 100mcap and would still be undervalued.

5p shortly, at this rate we might close between 7-8p

Gone into auction

Yes massively undervalued, they needed something to get this going and now rerating. Double digits may come alot sooner. Company values their shares in pounds not pennies.

If P140 is the only non-immunosuppressing therapy in clinical development in the industry how much will it be worth? No wonder they are getting signifcant interest.

Yes I think above 5p close will set us up nicely for next week heading towards double digits.

Usually get a good move after 11 possibly with some early US buyers. Wonder if Lanstead are out, moving freely now.

K3VMC you are going to have to do some research as doesn't mention on the presentation, just mentions peers at the similar stage products are valued at that.

However imm do mention their forecast for potential sales is valued at ~$4billion.

Look at those main leaders in autoimmunne disease which I posted yesterday to give an idea.

That drop provided a great opportunity for those looking to get in. Crazy to think we are still around 13mcap when valuation should be much higher. Peers are valued at £550-1.4billion.

Come 11 it will go, think we will be closer to 5p by end of play.

ImmuPharma aims to leverage these events to continue discussions about its P140 program, which has garnered significant interest from leading biopharmaceutical companies.

Them 7.3m warrants are the ones imm hold in another company incanthera.

Jamrock interims said they had Cash balance of £1.1m as at 30 June 2024

They have warrants at 2p which if all exercised will bring in around £1.89 million. So would think that would be sufficient for them. Will they raise now? Can't say they won't 100% but imo warrants will give them a strong balance.

As always DYOR and go through their presentation on their website to see how undervalued they are.

So similar stage would be looking at £550m-£1.4 billion

Imm mcap around £13mil, company are trying to say they are worth pounds not pennies.

F1 would still be undervalued compared to peers.

▪ Biotech company peers are valued at least 100x higher on average by the

markets

▪ Biotech’s with similar stage products valued ~$680-1750m

▪ ImmuPharma ~£13m

Merlin they were down to 6.9% in December so I would think they are out if not almost. Could get holdings rns after hours or tomorrow.

There are several gaps on the way up but someday that big one might fill from 50p to £1.47

If anyone is concerned about funds just know there are warrants at 2p if all exercised will bring in £1.89mil in funds. Giving them a healthy balance. Just note some options/warrants are higher at 5p, 10p, 11p and 52p.

Wonder if lanstead are out, had around 28mill shares left on Dec 10th, we have done nearly 65million in volume. Should get holdings rns if so and then it should really get going.

ImmuPharma value will be realised because….

▪ Mid to late-stage pipeline with significant product differentiation

▪ High medical need and commercially attractive markets

▪ Biotech company peers are valued at least 100x higher on average by the

markets

▪ Biotech’s with similar stage products valued ~$680-1750m

▪ ImmuPharma ~$10m